Success Stories: EB-1A Petition Approved for Research Associate in Washington with 79 Citations in the Field of Pharmaceutical Sciences (PP Requested)
Client’s Testimonial:
“Thanks for your efforts and well presenting my case.”
On January 27th, 2017, we received another EB-1A (Alien of Extraordinary Ability) approval for a Research Associate in the Field of Pharmaceutical Sciences (Approval Notice).
General Field: Pharmaceutical Sciences
Position at the Time of Case Filing: Research Associate
Country of Origin: India
Service Center: Nebraska Service Center (NSC)
State of Residence at the Time of Filing: Washington
Approval Notice Date: January 27th, 2017
Processing Time: 22 Days (Premium Processing Requested)
Case Summary:
A research associate from India received notification of EB-1A (Alien of Extraordinary Ability) petition approval just 22 days after filing. The reason for such rapid adjudication is because he upgraded his case to Premium Processing (PP) 12 days after we filed the case on his behalf. For an additional fee of $1,225, the USCIS guarantees that they will process petitions filed under PP within 15 calendar days.
Putting together a strong EB1A case:
We were hired to prove that our client has a sustained record of success, has national/international acclaim and is at the top of his field of pharmaceutical sciences. We did this by listing the 79 times his 7 publications were cited and the 19 times he conducted peer reviews for a variety of well-known scientific journals. We also noted his Ph.D. in Pharmacology and Nanotechnology as well as his work on the development of novel drug delivery systems and drug testing for clinical application.
We carefully reviewed his research and concluded that he is contributing significantly to the field of pharmaceutical sciences, extending the reasonable expectation that he will continue to do so within the United States. To support our argument that our client deserved to obtain EB1A petition approval, we included recommendation letters volunteered by other experts in the field. According to one of them: “Given the importance of his research to the public good of the United States, I recommend [Client] be allowed to continue his research indefinitely in the United States. He is one of very few researchers with the combined experience in nanotechnology and pharmacology capable of making further advancements in switchable controlled release devices.”
Taking the final step:
A little less than 2 months after his EB1A petition was approved, we filed I-485 applications for our client and his dependent. We are currently waiting for the USCIS to take action on these applications (approval means US permanent residency), and in the meantime, we wish our client the best as he continues to progress the field of pharmaceutical sciences.

